| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1000219265 |
| P356 | DOI | 10.2165/00019053-200321040-00006 |
| P698 | PubMed publication ID | 12600223 |
| P2093 | author name string | Peter A Singer | |
| Allan S Detsky | |||
| Anne M PausJenssen | |||
| P2860 | cites work | Guidelines for economic analysis of pharmaceutical products: a draft document for Ontario and Canada | Q33560116 |
| Priority setting in health care: learning from international experience | Q33578846 | ||
| Problems with the interpretation of pharmacoeconomic analyses: a review of submissions to the Australian Pharmaceutical Benefits Scheme | Q33903908 | ||
| Technology assessment and cost-effectiveness analysis: misguided guidelines? | Q34726939 | ||
| Cost-effectiveness and cost-benefit analyses in the medical literature. Are the methods being used correctly? | Q35861601 | ||
| Managed care pharmacy, socioeconomic assessments and drug adoption decisions | Q40886683 | ||
| Puzzling out priorities. Why we must acknowledge that rationing is a political process | Q42758751 | ||
| Australian economic evaluation and government decisions on pharmaceuticals, compared to assessment of other health technologies | Q50180439 | ||
| Quality assessment of economic evaluations in selected pharmacy, medical, and health economics journals. | Q53374474 | ||
| Do physicians take cost into account when making prescribing decisions? | Q53933542 | ||
| Update and evaluation of Australian guidelines. Government perspective | Q71903737 | ||
| Manufacturing consensus, marketing truth: guidelines for economic evaluation | Q72268705 | ||
| Hospital pharmacy decisions, cost containment, and the use of cost-effectiveness analysis | Q73517862 | ||
| Pharmacoeconomic analyses: making them transparent, making them credible | Q73737076 | ||
| Resource allocation: beyond evidence-based medicine and cost-effectiveness analysis | Q73969115 | ||
| The role of cost-consequence analysis in healthcare decision-making | Q77157475 | ||
| The second phase of priority setting. Goodbye to the simple solutions: the second phase of priority setting in health care | Q95815379 | ||
| P433 | issue | 4 | |
| P304 | page(s) | 285-294 | |
| P577 | publication date | 2003-01-01 | |
| P1433 | published in | PharmacoEconomics | Q7180778 |
| P1476 | title | Ontario's formulary committee: how recommendations are made | |
| P478 | volume | 21 |
| Q48572824 | Bridging health technology assessment (HTA) and efficient health care decision making with multicriteria decision analysis (MCDA): applying the EVIDEM framework to medicines appraisal |
| Q45421938 | Decision-makers' preferences for approving new medicines in Wales: a discrete-choice experiment with assessment of external validity |
| Q36635514 | Economic evaluation and decision making in the UK. |
| Q36309218 | Economic evaluations of healthcare programmes and decision making: the influence of economic evaluations on different healthcare decision-making levels |
| Q33395099 | Evidence and Value: Impact on DEcisionMaking--the EVIDEM framework and potential applications |
| Q37444256 | Health technology assessment: a comprehensive framework for evidence-based recommendations in Ontario |
| Q49579736 | Pitfalls of prioritizing cost-effectiveness in the assessment of medical innovation |
| Q50106369 | Pitfalls of prioritizing cost-effectiveness in the assessment of medical innovation: A comment on Wallis and Detsky editorial |
| Q24799303 | Priority setting for new technologies in medicine: a transdisciplinary study |
| Q35903591 | Priority setting for pharmaceuticals. The use of health economic evidence by reimbursement and clinical guidance committees |
| Q56903232 | Priority setting in a hospital drug formulary: a qualitative case study and evaluation |
| Q52104665 | Priority setting in surgery: improve the process and share the learning. |
| Q39781561 | Public and decision maker stated preferences for pharmaceutical subsidy decisions: a pilot study |
| Q46146753 | Reimbursement decisions of the All Wales Medicines Strategy Group: influence of policy and clinical and economic factors. |
| Q24794703 | Setting priorities in health care organizations: criteria, processes, and parameters of success |
| Q40735681 | The Role of Decision Models in Health Care Policy: A Case Study. |
| Q38074371 | The evaluation and use of economic evidence to inform cancer drug reimbursement decisions in Canada |
| Q33834292 | The evolution of the cancer formulary review in Canada: Can centralization improve the use of economic evaluation? |
| Q61737695 | Utilización de las evaluaciones económicas de intervenciones sanitarias |
| Q42861931 | What do district health planners in Tanzania think about improving priority setting using 'Accountability for reasonableness'? |
| Q80130925 | [Implementation of the guidelines for the introduction of new drugs (GINF) in Andalusian hospitals] |
Search more.